APRE · Aprea Therapeutics, Inc.

Aprea Therapeutics reported first quarter 2026 financial results, with a net loss of $3.3 million ($0.22 per share) compared to a net loss of $3.9 million ($0.66 per share) in the same period last year. The improvement was driven by a reduction in R&D expenses to $1.6 million from $2.5 million, primarily due to the voluntary pause of the ABOYA-119 trial evaluating ATRN-119. G&A expenses remained flat at $1.8 million. The company ended the quarter with $46.5 million in cash and cash equivalents, a significant increase from $14.6 million at year-end 2025, following the close of an oversubscribed $30 million private placement on March 31, 2026. The financing was led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management, existing investors, and insiders. Proceeds will support general corporate purposes and R&D, including expansion of the ACESOT-1051 trial to enroll at least 50 patients with uterine serous carcinoma and patients with cyclin E-overexpressing platinum-resistant ovarian cancer. Clinically, the company reported two partial responses in the ongoing Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051, with one confirmed at a second imaging assessment. Dose escalation continues, and additional data will be presented at ASCO 2026 on May 30. Management expressed confidence in the precision medicine strategy and the potential of APR-1051, citing encouraging tolerability and early efficacy signals. The company believes its cash runway extends into Q1 2028.